| [1] |
Joseph DBK, Strand DW, Vezina CM. DNA methylation in development and disease: an overview for prostate researchers[J]. Am J Clin Exp Urol, 2018,6(6): 197-218.
|
| [2] |
Hendrich B, Tweedie S. The methyl-CpG binding domain and the evolving role of DNA methylation in animals[J]. Trends Genet, 2003, 19(5): 269-277.
|
| [3] |
Schübeler D . Function and information content of DNA methylation[J]. Nature, 2015, 517(7534): 321-326.
|
| [4] |
Zhang ZM, Lu R, Wang PC, et al. Structural basis for DNMT3A-mediated de novo DNA methylation[J]. Nature, 2018, 554(7692): 387-391.
|
| [5] |
Ren WD, Gao LF, Song JK. Structural basis of DNMT1 and DNMT3A-Mediated DNA methylation[J]. Genes, 2018, 9(12), 62. DOI: 10.3390/genes9120620 |
| [6] |
Liu RE, Lang ZB. The mechanism and function of active DNA demethylation in plants[J]. J Integr Plant Biol, 2020, 62(1): 148-159.
|
| [7] |
Patra SK, Patra A, Zhao H, et al. DNA methyltransferase and demethylase in human prostate cancer[J]. Mol Carcinog, 2002, 33(3): 163-171.
|
| [8] |
Puto LA, Benner C,Hunter T. The DAXX co-repressor is directly recruited to active regulatory elements genome-wide to regulate autophagy programs in a model of human prostate cancer[J]. Oncoscience, 2015, 2(4): 362-72.
|
| [9] |
Hsieh P, Yamane K. DNA mismatch repair: Molecular mechanism, cancer, and ageing[J]. Mech Ageing Dev, 2008, 129(7-8): 391-407.
|
| [10] |
Basu S, Majumder S, Bhowal A, et al. A study of molecular signals deregulating mismatch repair genes in prostate cancer compared to benign prostatic hyperplasia[J]. PLoS One, 2015, 10(5): e0125560.
|
| [11] |
Feng XL, Wang ZM, Fillmore R, et al. MiR-200, a new star miRNA in human cancer[J]. Cancer Lett, 2014, 344(2): 166-173.
|
| [12] |
Lynch S, O'Neill K, McKenna M, et al. Regulation of mir-200c and mir-141 by methylation in prostate cancer[J]. Prostate, 2016, 76(13): 1146-1159.
|
| [13] |
Daniunaite K, Dubikaityte M, Gibas P, et al. Clinical significance of miRNA host gene promoter methylation in prostate cancer[J]. Hum Mol Genet, 2017, 26(13): 2451-2461.
|
| [14] |
Hoffmann MJ, Engers R, Florl AR, et al. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer[J]. Cancer Biol Ther, 2007, 6(9): 1403-1412.
|
| [15] |
Gravina GL, Ranieri G, Muzi P, et al. Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells[J]. Oncol Rep, 2013, 29(3): 1189-1195.
|
| [16] |
Chen MF, Chen WC, Chang YJ, et al. Role of DNA methyltransferase 1 in hormone-resistant prostate cancer[J]. J Mol Med(Berl), 2010, 88(9): 953-962.
|
| [17] |
Theodore SC, Davis M, Zhao F, et al. MicroRNA profiling of novel African American and Caucasian Prostate Cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltransferase 1[J]. Oncotarget, 2014, 5(11): 3512-3525.
|
| [18] |
Gao X, Mao YH, Xiao CT, et al. Calpain-2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NF-κB/DNMT1 signaling pathway[J]. Prostate, 2018, 78(9): 682-90.
|
| [19] |
Sengupta D, Deb M, Patra SK. Antagonistic activities of miR-148a and DNMT1: Ectopic expression of miR-148a impairs DNMT1 mRNA and dwindle cell proliferation and survival[J]. Gene, 2018, 660(20): 68-79.
|
| [20] |
Valdez CD, Kunju L, Daignault S, et al. The E2F1/DNMT1 Axis Is Associated With the Development of AR Negative Castration Resistant Prostate Cancer[J]. Prostate, 2013, 73(16): 1776-1785.
|
| [21] |
Tzelepi V, Logotheti S, Papakonstantinou E, et al. Epigenetics and prostate cancer: Defining the timing of DNA methyltransferases deregulation during prostate cancer progression[J]. Pathology, 2020, 52(2): 218-227.
|
| [22] |
Li LP, Li SQ. miR-205-5p inhibits cell migration and invasion in prostatic carcinoma by targeting ZEB1[J]. Oncol Let, 2018, 16(2): 1715-1721.
|
| [23] |
Nagesh PKB, Chowdhury P, Hatami E, et al.miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy[J]. Cancers, 2018, 10(9): 289.
|
| [24] |
Lynch S, O'Neill K, McKenna M, et al. Investigation of miR-205 expression and its methylation status in prostate cancer[J]. Cancer Res, 2018, 78(13): 4418.
|
| [25] |
Yaqinuddin A, Qureshi SA, Qazi R, et al. DNMT1 Silencing Affects Locus Specific DNA Methylation and Increases Prostate Cancer Derived PC3 Cell Invasiveness[J]. J Urol, 2009, 182(2): 756-761.
|
| [26] |
James SR, Cedeno CD, Sharma A, et al. DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11[J]. Epigenetics, 2013, 8(8): 849-863.
|
| [27] |
Lee E, Wang JC, Yumoto K, et al. DNMT1 Regulates epithelial-mesenchymal transition and cancer stem cells, which promotes prostate cancer metastasis[J]. Neoplasia, 2016, 18(9): 553-566.
|
| [28] |
Lee E, Wang JC, Jung Y, et al. Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer[J]. J Cell Biochem, 2018, 119(4): 3697-3705.
|
| [29] |
Melnik BC. Milk disrupts p53 and DNMT1, the guardians of the genome: implications for acne vulgaris and prostate cancer[J]. Nutr Metabo(Lond), 2017, 14: 55.
|
| [30] |
Lin HY, Kuo YC, Weng YI, et al. Activation of Silenced Tumor Suppressor Genes in Prostate Cancer Cells by a Novel Energy Restriction-Mimetic Agent[J]. Prostate, 2012, 72(16): 1767-1778.
|
| [31] |
Agarwal S, Amin KS, Jagadeesh S, et al. Mahanine restores RASSF1A expression by down-regulating DNMT1 and DNMT3B in prostate cancer cells[J]. Mol Cancer, 2013, 12: 99.
|
| [32] |
Boyanapalli S, Li WJ, Francisco Fuentes, et al. Epigenetic reactivation of RASSF1A by phenethyl isothiocyanate (PEITC) and promotion of apoptosis in LNCaP cells[J]. Pharmacol Res, 2016, 114: 175-184.
|
| [33] |
Kumar SR, Bryan JN, Esebua M, et al. Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma[J]. BMC Cancer, 2017, 17(1): 158.
|
| [34] |
Graça I, Sousa EJ, Costa-Pinheiro P, et al. Anti-neoplastic properties of hydralazine in prostate cancer[J]. Onco Target, 2014, 5(15): 5950-5964.
|
| [35] |
Sharma V, Verma V, Lal N, et al. Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re-expressing the epigenetically repressed tumor suppressor -estrogen receptor β[J]. Mol Carcinog, 2016, 55(11): 1843-1857.
|
| [36] |
Xiang ST, Zoua PL, Tang Q, et al. HOTAIR-mediated reciprocal regulation of EZH2 and DNMT1 contribute to polyphyllin I-inhibited growth of castration-resistant prostate cancer cells in vitro and in vivo[J]. Biochim Biophys Acta Gen Subj, 2017, 1862(3): 589-599.
|
| [37] |
Kardooni H, Gonzalez-Gualda E, Stylianakis E, et al. CRISPR-mediated reactivation of DKK3 expression attenuates TGF-β signaling in prostate cancer[J]. Cancers, 2018, 10(6): 165.
|
| [38] |
Du YF, Liang L, Shi Y, et al. Multi-target siRNA based on DNMT3A/B homologous conserved region influences cell cycle and apoptosis of human prostate cancer cell line TSU-PR1[J]. Genet Mol Biol, 2012, 35(1): 164-171.
|
| [39] |
Li X, Lv JC, Liu S. MCM3AP-AS1 KD Inhibits Proliferation, Invasion, and Migration of PCa Cells via DNMT1/DNMT3 (A/B) Methylation-Mediated Upregulation of NPY1R[J]. Mol Ther Nucleic Acids, 2020, 20: 265-278.
|
| [40] |
Yuan Y, Du Y, Wang L, et al. The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation[J]. J Cancer, 2020, 11(12): 3588-3595.
|
| [41] |
Cai JR, Yang F, Zhan HL, et al. RNA m6A Methyltransferase METTL3 Promotes The Growth Of Prostate Cancer By Regulating Hedgehog Pathway[J]. Onco Targets Ther, 2019, 12: 9143-9152.
|
| [42] |
Ma XX, Cao ZG, Zhao SL. m6A methyltransferase METTL3 promotes the progression of prostate cancer via m6A-modified LEF1. Eur Rev Med Pharmacol Sci, 2020, 24(7): 3565-3571.
|
| [43] |
Barros-Silva D, Lobo J, Guimarães-Teixeira C, et al. VIRMA-Dependent N6-Methyladenosine Modifications Regulate the Expression of Long Non-Coding RNAs CCAT1 and CCAT2 in Prostate Cancer[J]. Cancers (Basel), 2020, 12(4).
|
| [44] |
Li JF, Meng S, Xu MJ, et al. Downregulation of N6-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N6-methyladenosine levels[J]. Oncotarget, 2018, 9(3): 3752-3764.
|